Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Verrica Pharmaceuticals price target lowered to $12 from $20 at H.C. Wainwright » 07:38
05/31/22
05/31
07:38
05/31/22
07:38
VRCA

Verrica Pharmaceuticals

$2.00 /

+0.04 (+2.04%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat lowered the firm's price target on Verrica Pharmaceuticals to $12 from $20 and keeps a Buy rating on the shares after the company received a third Complete Response Letter for VP-102, a topical cantharidin drug-device for molluscum contagiosum. The analyst thinks moving to a new supplier is the likely course and still sees ultimate approval, 18 months later than expected.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$2.00 /

+0.04 (+2.04%)

VRCA Verrica Pharmaceuticals
$2.00 /

+0.04 (+2.04%)

05/25/22 Needham
Verrica Pharmaceuticals downgraded to Hold at Needham after CRL
05/25/22 Needham
Verrica Pharmaceuticals downgraded to Hold from Buy at Needham
05/25/22 RBC Capital
Verrica downgraded to Sector Perform from Outperform at RBC Capital
03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
VRCA Verrica Pharmaceuticals
$2.00 /

+0.04 (+2.04%)

VRCA Verrica Pharmaceuticals
$2.00 /

+0.04 (+2.04%)

Over a month ago
Downgrade
Verrica Pharmaceuticals downgraded to Hold at Needham after CRL » 11:36
05/25/22
05/25
11:36
05/25/22
11:36
VRCA

Verrica Pharmaceuticals

$2.25 /

-3.305 (-59.50%)

Needham analyst Serge…

Needham analyst Serge Belanger downgraded Verrica Pharmaceuticals to Hold from Buy and removed his previous price target on the shares after the company announced that the FDA has issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of molluscum contagiosum. This is the third CRL from the FDA for VP-102 and second CRL where CMO deficiencies at Sterling Pharmaceuticals prevented the agency from approving the product, noted Belanger. While Verrica is engaging a new CMO, there is likely to be a lengthy process to refiling and a delay of at least 12-months for FDA approval, said the analyst. While Belanger believes VP-102 has "a bright commercial future," Verrica's financing overhang is "now more difficult to address," the analyst added.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$2.25 /

-3.305 (-59.50%)

VRCA Verrica Pharmaceuticals
$2.25 /

-3.305 (-59.50%)

05/25/22 Needham
Verrica Pharmaceuticals downgraded to Hold from Buy at Needham
05/25/22 RBC Capital
Verrica downgraded to Sector Perform from Outperform at RBC Capital
03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
09/22/21 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $20 from $24 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$2.25 /

-3.305 (-59.50%)

VRCA Verrica Pharmaceuticals
$2.25 /

-3.305 (-59.50%)

Downgrade
Verrica Pharmaceuticals downgraded to Hold from Buy at Needham » 11:30
05/25/22
05/25
11:30
05/25/22
11:30
VRCA

Verrica Pharmaceuticals

$2.30 /

-3.255 (-58.60%)

Needham analyst Serge…

Needham analyst Serge Belanger downgraded Verrica Pharmaceuticals to Hold from Buy.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$2.30 /

-3.255 (-58.60%)

VRCA Verrica Pharmaceuticals
$2.30 /

-3.255 (-58.60%)

05/25/22 RBC Capital
Verrica downgraded to Sector Perform from Outperform at RBC Capital
03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
09/22/21 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $20 from $24 at H.C. Wainwright
09/21/21 Needham
Verrica Pharmaceuticals price target lowered to $20 from $22 at Needham
VRCA Verrica Pharmaceuticals
$2.30 /

-3.255 (-58.60%)

VRCA Verrica Pharmaceuticals
$2.30 /

-3.255 (-58.60%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:54
05/25/22
05/25
09:54
05/25/22
09:54
CASY

Casey's General Stores

$202.31 /

+0.86 (+0.43%)

, CME

CME Group

$193.50 /

+2.06 (+1.08%)

, APD

Air Products

$238.93 /

+2.2 (+0.93%)

, FANG

Diamondback Energy

$138.07 /

+2.25 (+1.66%)

, KRC

Kilroy Realty

$60.53 /

+1.13 (+1.90%)

, SBRA

Sabra Health Care

$13.73 /

+0.37 (+2.77%)

, BBY

Best Buy

$74.88 /

+1.37 (+1.86%)

, FSR

Fisker

$9.58 /

-0.03 (-0.31%)

, TWOU

2U

$9.41 /

-1.19 (-11.23%)

, DVN

Devon Energy

$70.62 /

+0.19 (+0.27%)

, VRCA

Verrica Pharmaceuticals

$2.37 /

-3.185 (-57.34%)

, ANCTF

Alimentation Couche-Tard

$43.00 /

-1.5 (-3.37%)

, MUSA

Murphy USA

$242.49 /

+0.33 (+0.14%)

, ARKO

Arko Corp.

$8.49 /

-0.03 (-0.35%)

, GNRC

Generac

$221.51 /

+5.82 (+2.70%)

, WBX

Wallbox

$9.83 /

-0.025 (-0.25%)

, ALGM

Allegro MicroSystems

$23.85 /

+0.13 (+0.55%)

, PRCH

Porch Group

$3.94 /

+0.105 (+2.74%)

Institutional investors…

ShowHide Related Items >><<
WBX Wallbox
$9.83 /

-0.025 (-0.25%)

VRCA Verrica Pharmaceuticals
$2.37 /

-3.185 (-57.34%)

TWOU 2U
$9.41 /

-1.19 (-11.23%)

SBRA Sabra Health Care
$13.73 /

+0.37 (+2.77%)

PRCH Porch Group
$3.94 /

+0.105 (+2.74%)

MUSA Murphy USA
$242.49 /

+0.33 (+0.14%)

KRC Kilroy Realty
$60.53 /

+1.13 (+1.90%)

GNRC Generac
$221.51 /

+5.82 (+2.70%)

FSR Fisker
$9.58 /

-0.03 (-0.31%)

FANG Diamondback Energy
$138.07 /

+2.25 (+1.66%)

DVN Devon Energy
$70.62 /

+0.19 (+0.27%)

CME CME Group
$193.50 /

+2.06 (+1.08%)

CASY Casey's General Stores
$202.31 /

+0.86 (+0.43%)

BBY Best Buy
$74.88 /

+1.37 (+1.86%)

ARKO Arko Corp.
$8.49 /

-0.03 (-0.35%)

APD Air Products
$238.93 /

+2.2 (+0.93%)

ANCTF Alimentation Couche-Tard
$43.00 /

-1.5 (-3.37%)

ALGM Allegro MicroSystems
$23.85 /

+0.13 (+0.55%)

CASY Casey's General Stores
$202.31 /

+0.86 (+0.43%)

05/25/22 Wells Fargo
Casey's General Stores initiated with an Overweight at Wells Fargo
03/10/22 Deutsche Bank
Casey's General Stores price target raised to $259 from $257 at Deutsche Bank
01/03/22 Stephens
Wendy's, Kirby and Vizio among Stephens' 2022 Best Ideas
12/09/21 Deutsche Bank
Casey's General Stores price target lowered to $256 from $264 at Deutsche Bank
CME CME Group
$193.50 /

+2.06 (+1.08%)

05/25/22 Oppenheimer
CME Group upgraded to Outperform from Perform at Oppenheimer
05/19/22 Deutsche Bank
CME Group price target lowered to $210 from $262 at Deutsche Bank
05/16/22 Argus
CME Group upgraded to Buy at Argus on higher rate and energy contract volumes
05/16/22 Argus
CME Group upgraded to Buy from Hold at Argus
APD Air Products
$238.93 /

+2.2 (+0.93%)

05/25/22 Atlantic Equities
Atlantic Equities upgrades Air Products on prospects of share recovery
05/25/22 Atlantic Equities
Air Products upgraded to Overweight from Neutral at Atlantic Equities
05/20/22 Credit Suisse
Air Products assumed with an Outperform at Credit Suisse
05/11/22 Wells Fargo
Air Products downgraded on mega project focus at Wells Fargo
FANG Diamondback Energy
$138.07 /

+2.25 (+1.66%)

05/25/22 Barclays
Diamondback Energy upgraded to Overweight from Equal Weight at Barclays
05/17/22 Wells Fargo
Diamondback Energy price target lowered to $200 from $204 at Wells Fargo
04/25/22 Susquehanna
Diamondback Energy price target raised to $167 from $152 at Susquehanna
04/21/22 Truist
Diamondback Energy price target raised to $200 from $170 at Truist
KRC Kilroy Realty
$60.53 /

+1.13 (+1.90%)

05/25/22 Goldman Sachs
Kilroy Realty upgraded to Buy from Neutral at Goldman Sachs
04/22/22 Mizuho
Mizuho upgrades Boston Properties, names top office REIT pick
04/14/22 Deutsche Bank
Kilroy Realty price target raised to $75 from $74 at Deutsche Bank
03/03/22 Evercore ISI
Evercore ISI shakes up Office REIT ratings with one upgrade, two downgrades
SBRA Sabra Health Care
$13.73 /

+0.37 (+2.77%)

05/25/22 Mizuho
Sabra Health Care upgraded to Buy from Neutral at Mizuho
04/18/22 Barclays
Sabra Health Care downgraded to Equal Weight from Overweight at Barclays
03/11/22 BofA
Sabra Health Care upgraded to Neutral from Underperform at BofA
02/22/22 Barclays
Sabra Health Care price target lowered to $16 from $19 at Barclays
BBY Best Buy
$74.88 /

+1.37 (+1.86%)

05/25/22 DA Davidson
Best Buy price target raised to $110 from $107 at DA Davidson
05/25/22 Guggenheim
Best Buy price target lowered to $100 from $130 at Guggenheim
05/25/22 Wedbush
Best Buy price target lowered to $75 from $80 at Wedbush
05/25/22 Barclays
Barclays downgrades Best Buy to Equal Weight on 'optimistic' guidance
FSR Fisker
$9.58 /

-0.03 (-0.31%)

05/25/22 Tudor Pickering
Fisker downgraded to Hold from Buy at Tudor Pickering
05/17/22 Credit Suisse
Fisker price target lowered to $20 from $25 at Credit Suisse
05/05/22 Cowen
Fisker price target lowered to $19 from $28 at Cowen
05/05/22 Barclays
Fisker price target lowered to $14 from $16 at Barclays
TWOU 2U
$9.41 /

-1.19 (-11.23%)

05/25/22 Piper Sandler
2U downgraded to Underweight from Neutral at Piper Sandler
05/09/22 Citi
Citi opens 'positive Catalyst Watch' on 2U, trims price target to $40
05/06/22 Barrington
2U price target lowered to $16 from $25 at Barrington
05/06/22 Needham
2U price target lowered to $19 from $28 at Needham
DVN Devon Energy
$70.62 /

+0.19 (+0.27%)

05/25/22 Barclays
Devon Energy downgraded to Equal Weight from Overweight at Barclays
05/24/22 Johnson Rice
Devon Energy downgraded to Accumulate from Buy at Johnson Rice
05/09/22 Raymond James
Devon Energy price target raised to $90 from $85 at Raymond James
05/04/22 Truist
Devon Energy price target raised to $100 from $91 at Truist
VRCA Verrica Pharmaceuticals
$2.37 /

-3.185 (-57.34%)

05/25/22 Needham
Verrica Pharmaceuticals downgraded to Hold at Needham after CRL
05/25/22 Needham
Verrica Pharmaceuticals downgraded to Hold from Buy at Needham
05/25/22 RBC Capital
Verrica downgraded to Sector Perform from Outperform at RBC Capital
03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
ANCTF Alimentation Couche-Tard
$43.00 /

-1.5 (-3.37%)

05/25/22 Wells Fargo
Alimentation Couche-Tard initiated with an Overweight at Wells Fargo
05/20/22 RBC Capital
Alimentation Couche-Tard price target raised to C$77 from C$73 at RBC Capital
03/22/22 Desjardins
Alimentation Couche-Tard price target raised to C$60 from C$59 at Desjardins
03/17/22 BMO Capital
Alimentation Couche-Tard price target raised to C$65 at BMO Capital
MUSA Murphy USA
$242.49 /

+0.33 (+0.14%)

05/25/22 Wells Fargo
Murphy USA initiated with an Equal Weight at Wells Fargo
04/19/22 Raymond James
Murphy USA price target raised to $260 from $215 at Raymond James
07/26/21 Raymond James
Murphy USA upgraded to Outperform from Market Perform at Raymond James
ARKO Arko Corp.
$8.49 /

-0.03 (-0.35%)

05/25/22 Wells Fargo
Arko Corp. initiated with an Equal Weight at Wells Fargo
GNRC Generac
$221.51 /

+5.82 (+2.70%)

05/25/22 Northland
Generac initiated with an Outperform at Northland
05/24/22 Roth Capital
Generac price target lowered to $320 from $555 at Roth Capital
05/23/22 Stephens
Generac's current level offers 'compelling entry point,' says Stephens
05/06/22 Guggenheim
Generac price target raised to $561 from $533 at Guggenheim
WBX Wallbox
$9.83 /

-0.025 (-0.25%)

05/25/22 Cowen
Wallbox initiated with an Outperform at Cowen
05/18/22 UBS
Wallbox price target lowered to $18 from $25 at UBS
03/31/22 Chardan
Wallbox initiated with a Buy at Chardan
12/06/21 UBS
Wallbox started with a Buy at UBS on low-risk residential EV charging potential
ALGM Allegro MicroSystems
$23.85 /

+0.13 (+0.55%)

05/25/22 Cowen
Allegro MicroSystems initiated with an Outperform at Cowen
05/11/22 Mizuho
Allegro MicroSystems price target lowered to $42 from $44 at Mizuho
04/25/22 Barclays
Allegro MicroSystems price target lowered to $31 from $35 at Barclays
04/20/22 Mizuho
Allegro MicroSystems price target lowered to $44 from $45 at Mizuho
PRCH Porch Group
$3.94 /

+0.105 (+2.74%)

05/25/22 Compass Point
Compass Point starts Porch Group at Buy, sees competitive advantages in network
05/25/22 Compass Point
Porch Group initiated with a Buy at Compass Point
05/23/22 JPMorgan
Porch Group initiated with an Overweight at JPMorgan
05/11/22 Craig-Hallum
Porch Group price target lowered to $8 from $13 at Craig-Hallum
VRCA Verrica Pharmaceuticals
$2.37 /

-3.185 (-57.34%)

TWOU 2U
$9.41 /

-1.19 (-11.23%)

SBRA Sabra Health Care
$13.73 /

+0.37 (+2.77%)

PRCH Porch Group
$3.94 /

+0.105 (+2.74%)

MUSA Murphy USA
$242.49 /

+0.33 (+0.14%)

KRC Kilroy Realty
$60.53 /

+1.13 (+1.90%)

GNRC Generac
$221.51 /

+5.82 (+2.70%)

FSR Fisker
$9.58 /

-0.03 (-0.31%)

FANG Diamondback Energy
$138.07 /

+2.25 (+1.66%)

DVN Devon Energy
$70.62 /

+0.19 (+0.27%)

CME CME Group
$193.50 /

+2.06 (+1.08%)

CASY Casey's General Stores
$202.31 /

+0.86 (+0.43%)

BBY Best Buy
$74.88 /

+1.37 (+1.86%)

ARKO Arko Corp.
$8.49 /

-0.03 (-0.35%)

APD Air Products
$238.93 /

+2.2 (+0.93%)

ALGM Allegro MicroSystems
$23.85 /

+0.13 (+0.55%)

  • 13
    Oct
TWOU 2U
$9.41 /

-1.19 (-11.23%)

FSR Fisker
$9.58 /

-0.03 (-0.31%)

BBY Best Buy
$74.88 /

+1.37 (+1.86%)

APD Air Products
$238.93 /

+2.2 (+0.93%)

ANCTF Alimentation Couche-Tard
$43.00 /

-1.5 (-3.37%)

VRCA Verrica Pharmaceuticals
$2.37 /

-3.185 (-57.34%)

TWOU 2U
$9.41 /

-1.19 (-11.23%)

PRCH Porch Group
$3.94 /

+0.105 (+2.74%)

KRC Kilroy Realty
$60.53 /

+1.13 (+1.90%)

GNRC Generac
$221.51 /

+5.82 (+2.70%)

FSR Fisker
$9.58 /

-0.03 (-0.31%)

FANG Diamondback Energy
$138.07 /

+2.25 (+1.66%)

CASY Casey's General Stores
$202.31 /

+0.86 (+0.43%)

BBY Best Buy
$74.88 /

+1.37 (+1.86%)

APD Air Products
$238.93 /

+2.2 (+0.93%)

ANCTF Alimentation Couche-Tard
$43.00 /

-1.5 (-3.37%)

WBX Wallbox
$9.83 /

-0.025 (-0.25%)

TWOU 2U
$9.41 /

-1.19 (-11.23%)

GNRC Generac
$221.51 /

+5.82 (+2.70%)

FSR Fisker
$9.58 /

-0.03 (-0.31%)

FANG Diamondback Energy
$138.07 /

+2.25 (+1.66%)

DVN Devon Energy
$70.62 /

+0.19 (+0.27%)

CASY Casey's General Stores
$202.31 /

+0.86 (+0.43%)

BBY Best Buy
$74.88 /

+1.37 (+1.86%)

Hot Stocks
Verrica Parmaceuticals trading resumes  09:39
05/25/22
05/25
09:39
05/25/22
09:39
VRCA

Verrica Pharmaceuticals

$5.56 /

-0.715 (-11.40%)

 
ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

05/25/22 RBC Capital
Verrica downgraded to Sector Perform from Outperform at RBC Capital
03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
09/22/21 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $20 from $24 at H.C. Wainwright
09/21/21 Needham
Verrica Pharmaceuticals price target lowered to $20 from $22 at Needham
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

Hot Stocks
Verrica Parmaceuticals trading halted, volatility trading pause  09:34
05/25/22
05/25
09:34
05/25/22
09:34
VRCA

Verrica Pharmaceuticals

$5.56 /

-0.715 (-11.40%)

 
ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

05/25/22 RBC Capital
Verrica downgraded to Sector Perform from Outperform at RBC Capital
03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
09/22/21 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $20 from $24 at H.C. Wainwright
09/21/21 Needham
Verrica Pharmaceuticals price target lowered to $20 from $22 at Needham
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

On The Fly
Fly Intel: Pre-market Movers » 09:11
05/25/22
05/25
09:11
05/25/22
09:11
WEN

Wendy's

$16.27 /

-0.4 (-2.40%)

, EXPR

Express

$2.38 /

-0.57 (-19.35%)

, BEEM

Beam Global

$12.77 /

-0.59 (-4.42%)

, DY

Dycom

$80.19 /

-0.72 (-0.89%)

, PLAB

Photronics

$15.05 /

-0.33 (-2.15%)

, DKS

Dick's Sporting

$71.49 /

-3.92 (-5.20%)

, VRCA

Verrica Pharmaceuticals

$5.56 /

-0.715 (-11.40%)

, IDCC

InterDigital

$60.79 /

+0.35 (+0.58%)

, KDNY

Chinook Therapeutics

$15.10 /

+0.335 (+2.27%)

, TWOU

2U

$10.60 /

-0.475 (-4.29%)

Check out this morning's…

ShowHide Related Items >><<
WEN Wendy's
$16.27 /

-0.4 (-2.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

TWOU 2U
$10.60 /

-0.475 (-4.29%)

PLAB Photronics
$15.05 /

-0.33 (-2.15%)

KDNY Chinook Therapeutics
$15.10 /

+0.335 (+2.27%)

IDCC InterDigital
$60.79 /

+0.35 (+0.58%)

EXPR Express
$2.38 /

-0.57 (-19.35%)

DY Dycom
$80.19 /

-0.72 (-0.89%)

DKS Dick's Sporting
$71.49 /

-3.92 (-5.20%)

BEEM Beam Global
$12.77 /

-0.59 (-4.42%)

WEN Wendy's
$16.27 /

-0.4 (-2.40%)

05/25/22 MKM Partners
Wendy's may see more 'value unlocks' from strategic options, says MKM Partners
05/25/22 Wedbush
Wedbush remains bullish on Wendy's, not surprised by Trian news
05/25/22 Stifel
Wendy's deal in 'low-$20 range' would be 'feasible,' says Stifel
05/12/22 Truist
Wendy's price target lowered to $27 from $29 at Truist
EXPR Express
$2.38 /

-0.57 (-19.35%)

06/04/21 B. Riley
Express price target raised to $4.50 from $3.50 at B. Riley
BEEM Beam Global
$12.77 /

-0.59 (-4.42%)

08/13/21 BTIG
Beam Global price target lowered to $42 from $50 at BTIG
06/07/21 Maxim
Beam Global on track to announce orders with large companies, says Maxim
DY Dycom
$80.19 /

-0.72 (-0.89%)

05/11/22 Wells Fargo
Dycom price target lowered to $110 from $120 at Wells Fargo
03/03/22 B. Riley
Dycom price target lowered to $115 from $120 at B. Riley
03/03/22 Wells Fargo
Dycom price target raised to $120 from $110 at Wells Fargo
01/27/22 UBS
Dycom initiated with a Buy at UBS
PLAB Photronics
$15.05 /

-0.33 (-2.15%)

04/11/22 Stifel
Photronics upgraded to Buy from Hold at Stifel
03/15/22 DA Davidson
DA Davidson 'bullish' on Photronics after CEO departure
08/26/21 DA Davidson
Photronics price target raised to $20 from $18 at DA Davidson
DKS Dick's Sporting
$71.49 /

-3.92 (-5.20%)

05/24/22 BofA
Dick's Sporting price target lowered to $130 from $160 at BofA
05/18/22 OTR Global
Dick's Sporting view downgraded to Mixed from Positive at OTR Global
05/11/22 Truist
Truist starts Academy Sports at Buy on durable trends and attractive valuation
04/13/22 Cleveland Research
Dick's Sporting comps on pace for beat in Q1-to-date, says Cleveland Research
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

05/25/22 RBC Capital
Verrica downgraded to Sector Perform from Outperform at RBC Capital
03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
09/22/21 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $20 from $24 at H.C. Wainwright
09/21/21 Needham
Verrica Pharmaceuticals price target lowered to $20 from $22 at Needham
IDCC InterDigital
$60.79 /

+0.35 (+0.58%)

08/03/21 Roth Capital
Court ruling sets tone for unlicensed Chinese OEMs in Europe, says Roth Capital
KDNY Chinook Therapeutics
$15.10 /

+0.335 (+2.27%)

02/01/22 H.C. Wainwright
H.C. Wainwright sees no negative read-through from Chinook CMO departure
TWOU 2U
$10.60 /

-0.475 (-4.29%)

05/25/22 Piper Sandler
2U downgraded to Underweight from Neutral at Piper Sandler
05/09/22 Citi
Citi opens 'positive Catalyst Watch' on 2U, trims price target to $40
05/06/22 Barrington
2U price target lowered to $16 from $25 at Barrington
05/06/22 Needham
2U price target lowered to $19 from $28 at Needham
WEN Wendy's
$16.27 /

-0.4 (-2.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

TWOU 2U
$10.60 /

-0.475 (-4.29%)

PLAB Photronics
$15.05 /

-0.33 (-2.15%)

KDNY Chinook Therapeutics
$15.10 /

+0.335 (+2.27%)

IDCC InterDigital
$60.79 /

+0.35 (+0.58%)

EXPR Express
$2.38 /

-0.57 (-19.35%)

DY Dycom
$80.19 /

-0.72 (-0.89%)

DKS Dick's Sporting
$71.49 /

-3.92 (-5.20%)

BEEM Beam Global
$12.77 /

-0.59 (-4.42%)

  • 25
    May
  • 10
    Nov
WEN Wendy's
$16.27 /

-0.4 (-2.40%)

TWOU 2U
$10.60 /

-0.475 (-4.29%)

EXPR Express
$2.38 /

-0.57 (-19.35%)

DKS Dick's Sporting
$71.49 /

-3.92 (-5.20%)

WEN Wendy's
$16.27 /

-0.4 (-2.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

TWOU 2U
$10.60 /

-0.475 (-4.29%)

PLAB Photronics
$15.05 /

-0.33 (-2.15%)

EXPR Express
$2.38 /

-0.57 (-19.35%)

DY Dycom
$80.19 /

-0.72 (-0.89%)

DKS Dick's Sporting
$71.49 /

-3.92 (-5.20%)

BEEM Beam Global
$12.77 /

-0.59 (-4.42%)

TWOU 2U
$10.60 /

-0.475 (-4.29%)

EXPR Express
$2.38 /

-0.57 (-19.35%)

DKS Dick's Sporting
$71.49 /

-3.92 (-5.20%)

BEEM Beam Global
$12.77 /

-0.59 (-4.42%)

Downgrade
Verrica downgraded to Sector Perform from Outperform at RBC Capital » 05:13
05/25/22
05/25
05:13
05/25/22
05:13
VRCA

Verrica Pharmaceuticals

$5.56 /

-0.715 (-11.40%)

RBC Capital analyst…

RBC Capital analyst Gregory Renza downgraded Verrica Pharmaceuticals to Sector Perform from Outperform with a price target of $4, down from $16, after the company received a Complete Response Letter from the FDA regarding its New Drug Application for VP-102 for the treatment of molluscum contagiosum. General contract manufacturing organization challenges continue to plague the filing, again standing in the way of an approval, Renza tells investors in a research note. The analyst downgrades the shares citing new uncertainty post the CRL.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
09/22/21 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $20 from $24 at H.C. Wainwright
09/21/21 Needham
Verrica Pharmaceuticals price target lowered to $20 from $22 at Needham
09/21/21 RBC Capital
Verrica Pharmaceuticals price target lowered to $16 from $19 at RBC Capital
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

Hot Stocks
Verrica Pharma gets FDA CRL for VP-102 in molluscum contagiosum treatment » 20:14
05/24/22
05/24
20:14
05/24/22
20:14
VRCA

Verrica Pharmaceuticals

$5.56 /

-0.715 (-11.40%)

Verrica Pharmaceuticals…

Verrica Pharmaceuticals "announced that the FDA has issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of molluscum contagiosum. The only deficiency listed in the CRL was related to the deficiencies identified at a general reinspection of Sterling Pharmaceuticals Services, LLC, the contract manufacturing organization that manufactures Verrica's bulk solution drug product. Sterling advised Verrica on May 20, 2022 that it received notice that it is on OAI status. Sterling's OAI classification resulted from a week-long reinspection of the CMO conducted by FDA in February 2022. The reinspection was conducted approximately 90 days after Sterling was originally classified by the Agency as VAI on November 17, 2021. Verrica understood that the VAI classification did not indicate that a reinspection was required. The CRL did not identify any other deficiencies. Moreover, none of the issues identified by FDA during the reinspection were specific to the manufacturing of VP-102. Additionally, Verrica was informed by the Division that it had completed its review of Verrica's NDA and product label, there were no open questions on the NDA review, and the VP-102 label was ready to be communicated. However, Verrica has been informed that internal FDA policy is preventing the Agency from communicating the label and approving the NDA when a CMO has an unresolved classification status or is placed on OAI status."

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
09/22/21 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $20 from $24 at H.C. Wainwright
09/21/21 Needham
Verrica Pharmaceuticals price target lowered to $20 from $22 at Needham
09/21/21 RBC Capital
Verrica Pharmaceuticals price target lowered to $16 from $19 at RBC Capital
VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

VRCA Verrica Pharmaceuticals
$5.56 /

-0.715 (-11.40%)

Earnings
Verrica Pharmaceuticals reports Q1 EPS (31c), consensus (47c) » 07:32
05/09/22
05/09
07:32
05/09/22
07:32
VRCA

Verrica Pharmaceuticals

$6.17 /

-0.19 (-2.99%)

Reports Q1 revenue…

Reports Q1 revenue $431,000, consensus $260,000. "This quarter, we achieved commercial readiness and entered the final stage of pre-launch operations as our PDUFA date approaches for VP-102, potentially the first treatment approved by the FDA to treat molluscum," said Ted White, Verrica's President and Chief Executive Officer. "We look forward to potentially bringing treatment and relief to thousands of patients, primarily children, suffering from molluscum, starting with a sales focus in Dermatology, Pediatric Dermatology and key academic centers and health systems." White continued: "We also dosed the first patient in our Phase 2 trial of LTX-315, a novel immunotherapy, in basal cell carcinoma, the most common type of cancer in the world. We are excited about this innovative, non-surgical approach to non-melanoma skin cancers. We expect to enroll over 60 patients in the trial and look forward to providing further updates."

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$6.17 /

-0.19 (-2.99%)

VRCA Verrica Pharmaceuticals
$6.17 /

-0.19 (-2.99%)

03/10/22 Brookline
Verrica Pharmaceuticals initiated with a Buy at Brookline
09/22/21 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $20 from $24 at H.C. Wainwright
09/21/21 Needham
Verrica Pharmaceuticals price target lowered to $20 from $22 at Needham
09/21/21 RBC Capital
Verrica Pharmaceuticals price target lowered to $16 from $19 at RBC Capital
VRCA Verrica Pharmaceuticals
$6.17 /

-0.19 (-2.99%)

VRCA Verrica Pharmaceuticals
$6.17 /

-0.19 (-2.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.